Category Archives: RedHill Biopharma Ltd

RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares

| November 8, 2017 | Asianet Pakistan | 0

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it intends to offer its American Depositary Shares […]

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

| October 3, 2017 | Asianet Pakistan | 0

BEKINDA®i 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo and comparing favorably with previously reported outcomes from studies of Xifaxan® (rifaximin) and Viberzi® (eluxadoline)ii IBS is one of the most common gastrointestinal disorders, affecting an estimated 30 million […]

RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn’s Disease

| July 31, 2017 | Asianet Pakistan | 0

The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the Phase III MAP US study To date, over 300 of the planned 410 subjects, have been randomized in the Phase III MAP US study […]

RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D

| July 17, 2017 | Asianet Pakistan | 0

Top-line results are expected in September 2017 The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D), with a primary endpoint of response in stool consistency as compared to baseline IBS is one of the most common […]

RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D

| April 24, 2017 | Asianet Pakistan | 0

op-line results are expected in the third quarter of 2017  The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D) IBS is one of the most common gastrointestinal disorders; it is estimated that at least 30 million […]

RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam®

| April 5, 2017 | Asianet Pakistan | 0

RedHill expects to initiate U.S. promotion of its two commercially-available gastrointestinal specialty products, Donnatal®1 and EnteraGam®2, in mid-2017 Under the terms of the agreement, RedHill will pay Entera Health royalties on net sales generated from the sale of EnteraGam® by RedHill TEL-AVIV, Israel, April 05, 2017 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) […]

RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma

| April 4, 2017 | Asianet Pakistan | 0

Orphan Drug designation allows RedHill to benefit from various development incentives to develop YELIVA® (ABC294640) for cholangiocarcinoma, as well as a seven-year marketing exclusivity period for the indication, if approved for marketing A Phase IIa clinical study with YELIVA® in patients with advanced, unresectable, intrahepatic and extrahepatic cholangiocarcinoma is planned to be initiated in the […]

RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results

| February 23, 2017 | Asianet Pakistan | 0

RedHill maintains a strong and debt-free balance sheet with approximately $66 million in cash and cash equivalents at the end of 2016, allowing the Company to continue to execute its development and U.S. commercialization plans Select 2016 milestones include: Successful final results from the first Phase III study with RHB-105 for the treatment of H. […]

To Top